Dengue infection during pregnancy and transplacental antibody transfer in Thai mothers

Perret, Cecilia; Chanthavanich, Pornthep; Pengsaa, Krisana; Limkittikul, Kriengsak; Hutajaroen, Pornsom; Bunn, James; Brabin, Bernard

doi:10.1016/j.jinf.2004.10.003

Cited by 69 publications

(61 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We used a murine model of early-life immunization and maternalantibody interference to model conditions in dengue-endemic areas. In such environments, most adult individuals are immune to one or more serotypes, and these antibodies are transferred passively from mothers to their infant children (45,63). Mice immunized as weanlings with two doses of DENV2 VRP 6 weeks apart showed similar titers regardless of maternal-antibody status (DENV naïve versus DENV immune).…”

Section: Discussionmentioning

confidence: 99%

An Immunogenic and Protective Alphavirus Replicon Particle-Based Dengue Vaccine Overcomes Maternal Antibody Interference in Weanling Mice

White

Parsons

Whitmore

et al. 2007

J Virol

View full text Add to dashboard Cite

Dengue viruses (DENV) are members of the family Flaviviridae and one of the most important groups of emerging viruses of global significance today (36, 66). There are four distinct antigenic serotypes (DENV1, DENV2, DENV3, and DENV4), all of which are capable of causing a spectrum of diseases in humans ranging from asymptomatic infections to debilitating classical dengue fever and severe and often fatal dengue hemorrhagic fever/dengue shock syndrome (DHF/ DSS) (36,68). DENV is transmitted to humans primarily by the mosquito Aedes aegypti. The lack of effective mosquito control, as well as demographic and economic changes, has contributed to the dramatic expansion and worldwide distribution of DENV epidemic activity in tropical and subtropical areas (36). It is estimated that up to 100 million infections and several hundred thousand cases of DHF/DSS occur each year, with more than 2.5 billion people living in areas at risk of infection in 2004 (21, 68). DHF is a leading cause of hospitalization and death among children in many countries in Southeast and South Asia, and the WHO has reported a rising trend in disease over the past decade (68). At the peak of epidemic times, as many as 70 children with severe DHF may present to a single hospital in a day, 20 of them with potentially fatal DSS (58). Although DHF/DSS in infants has not been comprehensively studied, it is estimated that more than 5% of all DHF/ DSS cases occur in infants (26,33,41,43,56,67,70).In the absence of vector control effective on a global scale, there is a clear need for a DENV vaccine. However, the development of a DENV vaccine has faced significant challenges that have resulted in the lack of a licensed vaccine after 70 years of research (17). In many areas where there is cocirculation of two or more serotypes, there is a high probability that individuals will be infected more than once in their lifetimes. Preexisting homotypic immunity protects from a secondary infection with the same serotype, and this protection seems to last for life (24,25). However, preexisting heterotypic nonneutralizing immunity to a secondary infection with a different DENV serotype is a risk factor for the development of severe DHF/DSS (23, 27, 61). These considerations suggest that a safe and efficacious DENV vaccine must be tetravalent and induce a long-term and balanced immune response to all four serotypes simultaneously in order to avoid sensitizing the vaccine recipient to a more severe outcome during a subsequent DENV infection. Additionally, primary infections during the first year of life that result in DHF/DSS have been associated with the presence of subneutralizing levels of maternal anti-DENV antibodies, which may increase the risk of enhanced infection and disease by antibody-mediated enhancement (26,33,41,56). To protect infants and children in dengue-endemic countries from severe dengue, the ideal DENV vaccine should

show abstract

Section: Discussionmentioning

confidence: 99%

An Immunogenic and Protective Alphavirus Replicon Particle-Based Dengue Vaccine Overcomes Maternal Antibody Interference in Weanling Mice

White

Parsons

Whitmore

et al. 2007

J Virol

View full text Add to dashboard Cite

show abstract

“…12 It has been proposed maternal age less than 20 years have high amount of circulating anti-dengue antibodies than those older than 20 years. 4 Children with lower weights are at higher risk of severe dengue.…”

Section: Discussionmentioning

confidence: 99%

“…Today fetal or cord blood samples are considered as a better source of qualifying intrauterine dengue infection. 4 In neonates, vertical transmission of dengue produce varying symptoms, from fever with thrombocytopenia to cerebral hemorrhage. 5 Due to lack of resources and capacity to survey dengue effectively and also reporting of vertical transmission of the virus is infrequent, very little is known about neonatal dengue.…”

Section: Introductionmentioning

confidence: 99%

Neonatal dengue

Thomas

George

2017

Int J Contemp Pediatr

View full text Add to dashboard Cite

Dengue infection is possible in all three trimesters of pregnancy. Dengue during pregnancy is associated with several neonatal complications such as perinatal death, miscarriage, low birth weight and preterm delivery. This is a case report of perinatal transmission of dengue in a baby who was born by an emergency caesarean section. The female baby was diagnosed with dengue fever as her dengue NS1 and ELISA tests were positive like her mother. Early recognition of congenital dengue will significantly reduce maternal and infant mortality. Proper management and supportive treatment is required for thrombocytopenia and hemorrhagic manifestations in dengue fever.

show abstract

“…En el cuadro 2 se presenta una revisión bibliográfica. En los estudios de seguimiento serológico de mujeres embarazadas en zonas endémicas del sudeste asiático, se han encontrado resultados positivos hasta de 94,7 %, pero de estas, solo el 0,8 % adquieren la infección durante el embarazo (11). En las madres, el cuadro clínico puede confundirse con el de otras condiciones, como toxemia y síndrome HELLP, teniendo en cuenta algunas características de dichas enfermedades, como, hiperbilirrubinemia y su asociación a hipertensión, aspectos que pueden ser útiles para hacer un diagnóstico diferencial en la mujer embarazada con dengue (12).…”

Section: Dengue De La Gestación Y Neonatalunclassified

Dengue perinatal: revisión de la literatura a propósito de un caso

et al. 2012

View full text Add to dashboard Cite

Contribución de los autores:Todos los autores participaron en el estudio del caso, la revisión del tema, la búsqueda bibliográfica y la redacción. PRESENTACIÓN DE CASO Biomédica 2013;33(Supl. El dengue es en la actualidad la enfermedad viral más relevante de transmisión vectorial hiperendémica en las Américas. El incremento en el número de casos se ha relacionado con la aparición de dengue durante la gestación y en el periodo neonatal. De acuerdo con la edad de gestación en la que ocurra la infección, podrían presentarse manifestaciones en el feto, como aborto, y en los pacientes a término, dengue neonatal. En este artículo se presenta una reseña de los casos reportados a nivel mundial, y especialmente en las Américas, así como aspectos fisiopatogénicos de la enfermedad.Palabras clave: dengue, fiebre hemorrágica dengue, recién nacido, síndrome HELLP. doi: http://dx.doi.org/10.7705/biomedica.v33i0.1449 Perinatal dengueDengue is currently the most important viral disease transmitted by arthropods and which is hyperendemic in the Americas. An increase in the number of cases is related to dengue during pregnancy and the neonatal period. According to the gestational age in which infection occurs, there could be different manifestations in the fetus including abortion, malformations or neonatal dengue in newborns. This article presents a review regarding some cases reported worldwide, especially in the Americas, and some pathophysiologic issues related to perinatal dengue.

show abstract

Dengue infection during pregnancy and transplacental antibody transfer in Thai mothers

Cited by 69 publications

References 16 publications

An Immunogenic and Protective Alphavirus Replicon Particle-Based Dengue Vaccine Overcomes Maternal Antibody Interference in Weanling Mice

An Immunogenic and Protective Alphavirus Replicon Particle-Based Dengue Vaccine Overcomes Maternal Antibody Interference in Weanling Mice

Neonatal dengue

Dengue perinatal: revisión de la literatura a propósito de un caso

Contact Info

Product

Resources

About